Clara Chen

Economic impact of disease progression in follicular non-Hodgkin lymphoma

Abstract Using a retrospective claims database, we estimated the economic costs of progression among patients with follicular non-Hodgkin lymphoma (f-NHL) treated in an outpatient community-based setting. Patients with f-NHL who received care between 1 July 2006 and 31 December 2009 were categorized into two cohorts based on whether they experienced progressive disease (PD) or not. Costs per patient per month (PPPM) were compared between patients with PD versus non-PD. Follow-up time was censored at the last entry for disease status or 6 months after the date of remission/stable disease or progression. Of the 1002 patients with f-NHL identified, 268 progressed and 734 did not. The mean overall costs PPPM over the 6-month follow-up period were significantly higher for patients with PD versus non-PD (

Elotuzumab Plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended 4‐Year Follow‐Up and Analysis of Relative Progression‐Free Survival From the Randomized ELOQUENT‐2 Trial

3527 vs.

Economic burden of multiple myeloma among patients in successive lines of therapy in the United States

860; difference =

Evaluation of Cardiovascular Comorbidities Among Patients with Multiple Myeloma in the United States

2667; p < 0.001). This cost difference persisted within all resource categories evaluated. Results of this study indicate that therapies which delay progression for patients with f-NHL may result in potential cost savings.

Front-Line (FL) Treatment Patterns Associated with Elderly Newly Diagnosed Multiple Myeloma (MM) Patients Treated in the US Community Setting

The randomized phase 3 ELOQUENT‐2 study (NCT01239797) evaluated the efficacy and safety of elotuzumab plus lenalidomide and dexamethasone (ELd) versus lenalidomide and dexamethasone (Ld) in relapsed/refractory multiple myeloma (RRMM), and to date, has the longest follow‐up of any monoclonal antibody in patients with RRMM.

Treatment Sequencing Patterns Associated with Elderly Patients with Relapsed/Refractory Multiple Myeloma (MM) in the US Community Setting

Abstract This study characterized the costs of multiple myeloma (MM) during first-line (1L), second-line (2L) and third-line (3L) treatment from the US payer perspective. Patients with ≥2 outpatient or ≥1 inpatient claims with a primary MM diagnosis and 12 months continuous enrollment post index were identified in a retrospective claims database between 1 July 2006 and 30 June 2013. A cost per-patient per-month (PPPM) metric was used to calculate total all-cause and anti-MM pharmacy costs in 1L, 2L, and 3L treatment. Of 5704 patients included, 3626 initiated 1L treatment, 1797 initiated 2L and 817 initiated 3L. Average total all-cause PPPM costs were

Assessing the Economic Burden in Medicare Patients with Multiple Myeloma

22,527 in 1L,

Characteristics, Treatment Patterns, and Survival Outcomes of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in North America (NA) and Europe: Findings from the PREAMBLE Study

35,266 in 2L and

Relative Progression-Free Survival Over Time with Novel Triplet Regimens for the Treatment of Relapsed/Refractory Multiple Myeloma

47,417 in 3L. Anti-MM pharmacy costs represented 22%, 29% and 29% of total all-cause costs PPPM in 1L, 2L and 3L, respectively. Study results suggest that delaying 2L and/or 3L treatment initiation may result in lower treatment costs for patients with MM.